Persistent idiopathic hyperphosphatasemia from bone alkaline phosphatase in a healthy boy.

ALPL gene Bone Enzymopathy Hypophosphatasia Isoenzyme Isoform Isozyme Mabry syndrome Osteoblast Phosphohydrolase Pyridoxal 5′-phosphate Skeleton Vitamin B(6)

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
09 2020
Historique:
received: 09 04 2020
revised: 26 05 2020
accepted: 26 05 2020
pubmed: 1 6 2020
medline: 22 6 2021
entrez: 1 6 2020
Statut: ppublish

Résumé

Alkaline phosphatase (ALP) in humans comprises a family of four cell-surface phosphomonoester phosphohydrolase isozymes. Three genes separately encode the "tissue-specific" ALPs whereas the fourth gene encodes ubiquitous homodimeric "tissue-nonspecific" ALP (TNSALP) richly expressed in bone, liver, kidney, and developing teeth. TNSALP monomers have five putative N-linked glycosylation sites where different post-translational modifications account for this isozyme's distinctive physicochemical properties in different organs. Three bone-derived TNSALP (BALP) isoforms (B/I, B1, and B2) are present in healthy serum, whereas a fourth BALP isoform (B1x) can circulate in chronic kidney disease. Herein, we report a healthy boy with persistent hyperphosphatasemia due to BALP levels two- to threefold higher than age-appropriate reference values. High-performance liquid chromatography, electrophoresis, heat inactivation, catalysis inhibition, and polyethylene glycol precipitation revealed increased serum B/I, B1, and B2 differing from patterns found in skeletal diseases. B/I was ~23-fold elevated. Absence of mental retardation and physical stigmata excluded Mabry syndrome, the ALP-anchoring disorder causing hyperphosphatasemia. Routine biochemical studies indicated intact mineral homeostasis. Serum N-terminal propeptide of type I procollagen (P1NP) level was normal, but C-terminal cross-linking telopeptide of type I collagen (CTX) level was elevated. However, radiological studies showed no evidence for a generalized skeletal disturbance. Circulating pyridoxal 5'-phosphate, a TNSALP natural substrate, was not low despite the laboratory hyperphosphatasemia, thereby suggesting BALP phosphohydrolase activity was not elevated endogenously. Mutation analysis of the ALPL gene encoding TNSALP revealed no defect. His non-consanguineous healthy parents had serum total ALP activity and BALP protein levels that were normal. Our patient's sporadic idiopathic hyperphosphatasemia could reflect altered post-translational modification together with increased expression and/or impaired degradation of BALP.

Identifiants

pubmed: 32474245
pii: S8756-3282(20)30239-8
doi: 10.1016/j.bone.2020.115459
pii:
doi:

Substances chimiques

Isoenzymes 0
Minerals 0
Alkaline Phosphatase EC 3.1.3.1

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115459

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Michael P Whyte (MP)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO 63110, USA; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO 63110, USA. Electronic address: mwhyte@shrinenet.org.

Nina S Ma (NS)

Division of Endocrinology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: nina.ma@childrenscolorado.org.

Steven Mumm (S)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO 63110, USA; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO 63110, USA. Electronic address: smumm@wustl.edu.

Gary S Gottesman (GS)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO 63110, USA. Electronic address: ggottesman@shrinenet.org.

William H McAlister (WH)

Mallinckrodt Institute of Radiology, Washington University School of Medicine at St. Louis Children's Hospital, St. Louis, MO 63110, USA. Electronic address: mcalisterw@wustl.edu.

Angela R Nenninger (AR)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO 63110, USA. Electronic address: anenninger@shrinenet.org.

Vinieth N Bijanki (VN)

Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO 63110, USA. Electronic address: vbijanki@shrinenet.org.

Karen L Ericson (KL)

Department of Chemistry, Purdue University-Fort Wayne, Fort Wayne, IN 46805, USA. Electronic address: ericsonk@pfw.edu.

Per Magnusson (P)

Department of Clinical Chemistry and Department of Biomedical and Clinical Sciences, Linköping University, SE-58185 Linköping, Sweden. Electronic address: per.magnusson@regionostergotland.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH